ClinicalTrials.gg
CompletedNCT03738618RITA-2Updated Jan 18, 2024Results posted

Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)

A Phase 3 interventional study of Follitropin delta and Placebo in Infertility, Female, sponsored by Ferring Pharmaceuticals. Completed at 24 sites in United States. Open to female participants aged 35 Years to 42 Years. Per ClinicalTrials.gov, last updated 2024-01-18.

Sponsored by Ferring Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
588
Allocation
Randomized
Ages
35 Years to 42 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies in Infertility, Female with a site in United States — 22 open to participants now, 25 under way, none of them phase 3. Infertility, Female · United States.

Enrollment
2nd of 47
588 · median 50
Started
2018
with 3 others
Phase 3
3 of 65
none open now
Registered
21st of 65
by date

Among the 65 studies in Infertility, Female with a site in United States, this one is the 2nd largest by enrollment of the 47 interventional ones that give a count, is one of 4 that started in 2018, is one of 3 in phase 3, and was the 21st registered.

Infertility, Female

552 studies on the registry are indexed under Infertility, Female; 135 are open to participants now.

Browse Infertility, Female studies →

Open to participants now

22 of the 65 studies in Infertility, Female with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Infertility, Female studies recruiting now, 11 (12%) set no upper age limit and 79 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.

This study: 35 Years to 42 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Infertility, Female with a site in United States, or all of them as a file.
02

Study summary

This trial investigates the effects of FE 999049 compared to placebo.

03

Conditions studied

  • Infertility, Female

Browse trials for

04

Who can participate

Ages eligible
35 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documents signed prior to any trial-related procedure.
  • In good physical and mental health in the judgement of the investigator.
  • Pre-menopausal women between the ages of 35 and 42 years. The participants must be at least 35 years (including the 35th birthday) when they sign the informed consent and no more than 42 years (up to the day before the 42nd birthday) at the time of randomization.
  • (BMI) between 17.5 and 38.0 kg/m\^2 (both inclusive) at screening.
  • Infertile women diagnosed with tubal infertility, unexplained infertility, endometriosis stage I/II or with partners diagnosed with male factor infertility, eligible for in vitro fertilization (IVF) and/or intracytoplasmic sperm injection (ICSI) using fresh or frozen ejaculated sperm from male partner or sperm donor.
  • Documented history of infertility for at least 6 months before randomization (not applicable in case of tubal or severe male factor infertility, or when the use of donor sperm is indicated).
  • Regular menstrual cycles of 24-35 days (both inclusive).
  • Hysterosalpingography, hysteroscopy or saline infusion sonography, documenting a uterus consistent with expected normal function (e.g. no evidence of clinically interfering uterine fibroids defined as submucous fibroids of any size or intramural fibroids larger than 3 cm in diameter, no polyps and no congenital structural abnormalities which are associated with a reduced chance of pregnancy) at screening or within 1 year prior to screening.
  • Transvaginal ultrasound documenting presence and adequate visualization of both ovaries, without evidence of significant abnormality (e.g. enlarged ovaries which would contraindicate the use of gonadotropins) and normal adnexa (e.g. no hydrosalpinx) at screening. Both ovaries must be accessible for oocyte retrieval.
  • Early follicular phase (cycle day 2-4) serum levels of FSH between 1 and 15 IU/L (results obtained within 3 months prior to randomization).
  • Negative serum Surface Antigen (HBsAg), Virus (HCV) and (HIV) antibody tests at screening or within 6 months prior to screening.
  • Willing to accept the blastocyst transfer policy for the fresh cycle and the cryopreserved cycles initiated within 12 months from the start of controlled ovarian stimulation using blastocysts obtained in this trial, i.e. transfer of one blastocyst (if a good-quality blastocyst is available) or transfer of one or two blastocysts (if no good-quality blastocyst is available).

Exclusion criteria

Exclusion Criteria:

  • More than one previous controlled ovarian stimulation cycle for IVF/ICSI.
  • Known endometriosis stage III-IV (defined by the revised ASRM classification, 2012).
  • Known history of anovulation.
  • One or more follicles greater than or equal to 10 mm (including cysts) observed on the transvaginal ultrasound prior to randomization on stimulation day 1.
  • Known history of recurrent miscarriage (defined as three consecutive losses after ultrasound confirmation of pregnancy [excluding ectopic pregnancy] and before week 24 of pregnancy).
  • Known abnormal karyotype of participant or of her partner / sperm donor, as applicable, depending on source of sperm used for insemination in this trial. In case partner sperm will be used and the sperm production is severely impaired (concentration less than 1 million/mL), normal karyotype, including no Y-chromosome microdeletion, must be documented.
  • Any known systemic disease (e.g. insulin-dependent diabetes).
  • Known inherited or acquired thrombophilia.
  • Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.
  • Any known endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney) with the exception of pharmacologically controlled sub-clinical hypothyroidism.
  • Known tumors of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus which would contraindicate the use of gonadotropins.
  • Known moderate or severe impairment of renal or hepatic function.
  • Any abnormal finding of clinical chemistry, hematology, thyroid-stimulating hormone (TSH) or prolactin, or vital signs at screening, which is judged clinically significant by the investigator.
  • Known abnormal cervical cytology of clinical significance observed within three years prior to randomization (unless the clinical significance has been resolved).
  • Findings at the gynecological examination at screening which preclude gonadotropin stimulation or are associated with a reduced chance of pregnancy, e.g. congenital uterine abnormalities or retained intrauterine device.
  • Pregnancy (negative urinary pregnancy tests must be documented at screening and prior to randomization) or to pregnancy.
  • Known current active pelvic inflammatory disease.
  • Use of fertility modifiers during the last menstrual cycle before randomization, including dehydroepiandrosterone (DHEA), metformin or cycle programming with oral , progestogen or estrogen preparations.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
588 participants (actual)

Study arms

  • Experimental
    FE 999049 (Follitropin Delta)

    Drug: Follitropin delta

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • FE 999049 was administered as single daily subcutaneous injections in the abdomen at a starting dose of 15 μg daily that was fixed for the first four stimulation days. Based on ovarian response, the dose could be adjusted by 3 μg, with dose increases implemented not more frequently than once every 2 days and dose decreases implemented per investigator's judgement. The minimum daily dose was 6 μg, and the maximum daily dose was 24 μg. Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early ovarian hyperstimulation syndrome (OHSS) with the exception of gonadotropin-releasing hormone (GnRH) agonist for triggering of final follicular maturation, was not allowed

    Also known as: FE 999049, REKOVELLE

  • DrugPlacebo

    Placebo was administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049. Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early OHSS with the exception of GnRH agonist for triggering of final follicular maturation, was not allowed.

06

What researchers measure

Primary outcomes

  1. Cumulative Ongoing Pregnancy Rate After the Fresh Cycle and Cryopreserved Cycles Initiated Within 12 Months From the Start of Controlled Ovarian Stimulation (COS)

    Defined as at least one intrauterine viable fetus 8-9 weeks after transfer. Data in this endpoint are presented for the fresh cycle and the cryopreserved cycles.

    Time frame: 8-9 weeks after transfer (up to approximately 16 months after start of stimulation)

Secondary outcomes

  1. Ongoing Pregnancy Rate in the Fresh Cycle and in the Cryopreserved Cycles

    Defined as at least one intrauterine viable fetus 8-9 weeks after transfer. Data in this endpoint are presented for the fresh cycle and the cryopreserved cycles.

    Time frame: 8-9 weeks after transfer (up to approximately 16 months after start of stimulation)

  2. Time From Start of COS to Ongoing Pregnancy Across the Fresh and Cryopreserved Cycles, Including Duration

    Time from start of COS to ongoing pregnancy, including both the fresh and cryopreserved cycles. In the placebo group, no participants achieved an ongoing pregnancy either after 12 calendar months or after 12 study months.

    Time frame: 8-9 weeks after transfer (up to approximately 16 months after start of stimulation)

  3. Time From Start of COS to Ongoing Pregnancy Across the Fresh and Cryopreserved Cycles, Measured in Number of Cycles Before Achieving Ongoing Pregnancy

    Time from start of COS to ongoing pregnancy, including both the fresh and cryopreserved cycles, measured in number of cycles before achieving ongoing pregnancy. In the placebo group, no participants achieved an ongoing pregnancy either after 12 calendar months or after 12 study months.

    Time frame: 8-9 weeks after transfer (up to approximately 16 months after start of stimulation)

  4. Ongoing Implantation Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively

    Defined as the number of intrauterine viable fetuses 8-9 weeks after transfer divided by number of blastocysts transferred. Data in this endpoint are presented for the fresh cycle, the cryopreserved cycles, and all cycles. One participant can contribute with a range from zero to multiple blastocysts. Data is not shown for placebo arm because no subjects underwent blastocyst transfer in the fresh cycle or cryopreserved cycles. '%' in the unit of measure refers to 'percentage'.

    Time frame: 8-9 weeks after transfer (up to approximately 16 months after start of stimulation)

  5. Clinical Pregnancy Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively

    Defined at least one gestational sac 5-6 weeks after transfer. Data in this endpoint are presented for the fresh cycle, the cryopreserved cycles, and all cycles.

    Time frame: 5-6 weeks after transfer (up to approximately 15 months after start of stimulation)

  6. Vital Pregnancy Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively

    Defined at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after transfer. Data in this endpoint are presented for the fresh cycle, the cryopreserved cycles, and all cycles.

    Time frame: 5-6 weeks after transfer (up to approximately 15 months after start of stimulation)

  7. Implantation Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively

    Defined as the number of gestational sacs 5-6 weeks after transfer divided by number of blastocysts transferred. The endpoint are presented for the fresh cycle, the cryopreserved cycles, and all cycles. One participant can contribute with a range from zero to multiple blastocysts. Data is not shown for placebo arm because no subjects underwent blastocyst transfer in the fresh cycle or cryopreserved cycles. '%' in the unit of measure refers to 'percentage'.

    Time frame: 5-6 weeks after transfer (up to approximately 15 months after start of stimulation)

  8. Positive Beta Human Chorionic Gonadotropin (βhCG) Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively

    Defined as positive serum βhCG test 10-14 days after transfer. Data in this endpoint are presented for the fresh cycle, the cryopreserved cycles, and all cycles.

    Time frame: 10-14 days after transfer (up to approximately 14 months after start of stimulation)

  9. Proportion of Subjects in the Fresh Cycle With Triggering of Final Follicular Maturation (With hCG, With GnRH Agonist, and in Total), Cycle Cancellation and Transfer Cancellation

    Data in this endpoint are presented for the fresh cycle.

    Time frame: Up to 5 days after oocyte retrieval (up to 27 days after start of stimulation)

  10. Number of Follicles on Stimulation Day 5

    The total number of follicles and the number of follicles per size category are reported.

    Time frame: On stimulation day 5

  11. Number of Follicles at End-of-stimulation

    The total number of follicles and the number of follicles per size category are reported.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  12. Size of Follicles on Stimulation Day 5

    Counted by ultrasound for the right and left ovary for each participant.

    Time frame: On stimulation day 5

  13. Size of Follicles at End-of-stimulation

    Counted by ultrasound for the right and left ovary for each participant.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  14. Number of Oocytes Retrieved

    The number of oocytes retrieved was recorded at the oocyte retrieval visit.

    Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)

  15. Proportion of Subjects With <4, 4-7, 8-14, 15-19 and ≥20 Oocytes Retrieved

    Grouped according to the number of oocytes retrieved. Participants with cycle cancellation due to poor ovarian response are included in the \<4 oocytes group.

    Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)

  16. Number of Metaphase II Oocytes

    The number of MII oocytes to oocytes retrieved for participants where all oocytes were inseminated using ICSI are presented.

    Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)

  17. Number of Fertilized Oocytes

    An oocyte was defined as fertilized if it had 2 pronuclei (2PN) at 19h (±2h).

    Time frame: On day 1 after oocyte retrieval (up to 23 days after start of stimulation)

  18. Fertilization Rate

    The fertilization rate was defined as the number of 2PN oocytes divided by the number of oocytes retrieved. Fertilization rate relative to oocytes retrieved has been reported.

    Time frame: On day 1 after oocyte retrieval (up to 23 days after start of stimulation)

  19. Number and Quality of Blastocysts on Day 5 After Oocyte Retrieval

    Number of blastocysts (total and good-quality) on Day 5 are presented. The quality evaluation of blastocysts consisted of assessment of three parameters, as per the Gardner \& Schoolcraft system: blastocyst expansion and hatching status (graded: 1-6), inner cell mass (graded: A-D) and trophectoderm (graded: A-D). A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher.

    Time frame: On day 5 after oocyte retrieval

  20. Endometrial Thickness on Stimulation Day 5

    Mean endometrial thickness is reported.

    Time frame: On stimulation day 5

  21. Endometrial Thickness at End-of-stimulation

    Mean endometrial thickness is reported.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  22. Echogenicity Pattern on Stimulation Day 5

    The distribution of participants with hypoechogenic, isoechogenic, or hyperechogenic endometrium is reported

    Time frame: On stimulation day 5

  23. Echogenicity Pattern at End-of-stimulation

    The distribution of participants with hypoechogenic, isoechogenic, or hyperechogenic endometrium is reported.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  24. Oocyte Utilization Rate

    Defined as the number of blastocysts transferred or cryopreserved divided by the number of oocytes retrieved. Data in this endpoint are presented for the cryopreserved cycles.

    Time frame: On day of oocyte retrieval up to 12 months after start of COS

  25. Oocyte Efficiency Index

    Defined as the cumulative number of ongoing pregnancies per oocyte retrieved. Data in this endpoint are presented for the cryopreserved cycles. The unit of measure for this endpoint is 'cumulative ongoing pregnancies/oocyte retrieved'.

    Time frame: 8-9 weeks after transfer

  26. Percentage of Blastocysts Surviving Cryopreservation

    Data in this endpoint are presented for the cryopreserved cycles. The unit is number of blastocysts with observations. One participant can contribute with a range from zero to multiple blastocysts.

    Time frame: 0 hour (+0.5 hour) after thawing

  27. Percentage of Blastocysts With Re-expansion After Cryopreservation

    Data in this endpoint are presented for the cryopreserved cycles. The unit is number of blastocysts with observations. One participant can contribute with a range from zero to multiple blastocysts.

    Time frame: 2.5 hour (±0.5 hour) after thawing

  28. Number of Cryopreserved Cycles Initiated Within 12 Months From the Start of COS

    The total number of cryopreserved cycles initiated are reported. Data in this endpoint are presented for the cryopreserved cycles. One participant can contribute with a range from zero to multiple blastocysts.

    Time frame: Up to 12 months after start of stimulation

  29. Number of Cryopreserved Cycles With Blastocyst Transfer

    The total number of cryopreserved cycles with blastocyst transfer are reported. Data in this endpoint are presented for the cryopreserved cycles. One participant can contribute with a range from zero to multiple blastocysts.

    Time frame: Up to 12 months after start of stimulation

  30. Circulating Concentrations of Anti-mullerian Hormone (AMH)

    Blood samples for analysis of circulating concentrations of AMH were drawn. The median and inter-quartile range (IQR) of AMH levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.

    Time frame: From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)

  31. Circulating Concentrations of Follicle-stimulating Hormone (FSH)

    Blood samples for analysis of circulating concentrations of FSH were drawn. The median and IQR of FSH levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.

    Time frame: From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)

  32. Circulating Concentrations of Luteinizing Hormone (LH)

    Blood samples for analysis of circulating concentrations of LH were drawn. The median and IQR of LH levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.

    Time frame: From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)

  33. Circulating Concentrations of Estradiol

    Blood samples for analysis of circulating concentrations of estradiol were drawn. The median and IQR of estradiol levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.

    Time frame: From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)

  34. Circulating Concentrations of Progesterone

    Blood samples for analysis of circulating concentrations of progesterone were drawn. The median and IQR of progesterone levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.

    Time frame: From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)

  35. Circulating Concentrations of Inhibin A

    Blood samples for analysis of circulating concentrations of inhibin A were drawn. The median and IQR of inhibin A levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.

    Time frame: From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)

  36. Circulating Concentrations of Inhibin B

    Blood samples for analysis of circulating concentrations of inhibin B were drawn. The median and IQR of inhibin B levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.

    Time frame: From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)

  37. Total Gonadotropin Dose

    Calculated by start dates, end dates and daily dose of IMP.

    Time frame: Up to 20 stimulation days

  38. Number of Stimulation Days

    Calculated by start dates and end dates.

    Time frame: Up to 20 stimulation days

  39. Proportion of Participants With Investigator-requested Gonadotropin Dose Adjustments

    Investigator-requested decreases and increases of the gonadotropin dose.

    Time frame: Stimulation Day 5

  40. Percentage of Participants With Adverse Events (AEs)

    Any AE occurring after start of IMP and before the end-of-trial visit, or a pre-treatment AE or pre-existing medical condition that worsens in intensity after start of IMP and before the end-of-trial visit was considered treatment-emergent, and is presented for this endpoint. Data in this endpoint are presented for the fresh cycle.

    Time frame: From time of signing informed consent until the end-of-cycle visit in the fresh cycle (approximately 6 months)

  41. Intensity of AEs

    The intensity of AE was classified using the following 3-point scale: mild = awareness of signs or symptoms, but no disruption of usual activity; moderate = event sufficient to affect usual activity (disturbing); or severe = inability to work or perform usual activities (unacceptable). Data in this endpoint are presented for the fresh cycle.

    Time frame: From time of signing informed consent until the end-of-cycle visit in the fresh cycle (up to approximately 6 months)

  42. Changes in Circulating Levels of Clinical Chemistry Compared to Baseline: Albumin, Protein

    Blood samples were collected for the analysis of clinical chemistry parameters including: Albumin and protein. Data in this endpoint are presented for the fresh cycle.

    Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)

  43. Changes in Circulating Levels of Clinical Chemistry Compared to Baseline: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase and Gamma Glutamyl Transferase

    Blood samples were collected for the analysis of clinical chemistry parameters including: Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase and gamma glutamyl transferase. Data in this endpoint are presented for the fresh cycle.

    Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)

  44. Changes in Circulating Levels of Clinical Chemistry Compared to Baseline: Bicarbonate, Blood Urea Nitrogen, Calcium, Chloride, Cholesterol, Glucose, Phosphate, Potassium and Sodium

    Blood samples were collected for the analysis of clinical chemistry parameters including: Bicarbonate, blood urea nitrogen, calcium, chloride, cholesterol, glucose, Phosphate, Potassium and Sodium. Data in this endpoint are presented for the fresh cycle.

    Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)

  45. Changes in Circulating Levels of Clinical Chemistry Compared to Baseline: Direct Bilirubin, Total Bilirubin, Creatinine, Urate

    Blood samples were collected for the analysis of clinical chemistry parameters including: Direct bilirubin, total bilirubin, creatinine, urate. Data in this endpoint are presented for the fresh cycle.

    Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)

  46. Changes in Circulating Levels of Clinical Chemistry Compared to Baseline: Lactate Dehydrogenase

    Blood samples were collected for the analysis of clinical chemistry parameters including: Lactate dehydrogenase. Data in this endpoint are presented for the fresh cycle.

    Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)

  47. Changes in Haematology Parameters Compared to Baseline: Erythrocytes

    Blood samples were collected for the analysis of haematology parameter including: Erythrocytes. Data in this endpoint are presented for the fresh cycle.

    Time frame: From screening to the end-of-cycle visit in the fresh cycle (approximately 6 months)

  48. Changes in Haematology Parameters Compared to Baseline: Haemoglobin

    Blood samples were collected for the analysis of haematology parameters including: Haemoglobin. Data in this endpoint are presented for the fresh cycle.

    Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)

  49. Changes in Haematology Parameters Compared to Baseline: Haematocrit

    Blood samples were collected for the analysis of haematology parameter including: Haematocrit. Data in this endpoint are presented for the fresh cycle.

    Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)

  50. Changes in Haematology Parameters Compared to Baseline: Erythrocyte Mean Corpuscular Volume

    Blood samples were collected for the analysis of haematology parameter including: Erythrocyte mean corpuscular volume. Data in this endpoint are presented for the fresh cycle.

    Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)

  51. Changes in Haematology Parameters Compared to Baseline: Leukocytes and Platelets

    Blood samples were collected for the analysis of haematology parameters including: Leukocytes and platelets. Data in this endpoint are presented for the fresh cycle.

    Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)

  52. Changes in Haematology Parameters Compared to Baseline: Erythrocyte Mean Corpuscular Hemoglobin

    Blood samples were collected for the analysis of haematology parameter including: Erythrocyte mean corpuscular haemoglobin. Data in this endpoint are presented for the fresh cycle.

    Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)

  53. Changes in Haematology Parameters Compared to Baseline: Erythrocyte Mean Corpuscular Haemoglobin Concentration

    Blood samples were collected for the analysis of haematology parameter including: Erythrocyte mean corpuscular haemoglobin concentration. Data in this endpoint are presented for the fresh cycle.

    Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)

  54. Changes in Haematology Parameters Compared to Baseline: Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/Leukocytes and Neutrophils/Leukocytes

    Blood samples were collected for the analysis of haematology parameters including: Basophils/leukocytes, eosinophils/ leukocytes, lymphocytes/leukocytes, monocytes/leukocytes and neutrophils/leukocytes. Data in this endpoint are presented for the fresh cycle.

    Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)

  55. Proportion of Subjects With Markedly Abnormal Changes of Clinical Chemistry Parameters: Alanine Aminotransferase, Aspartate Aminotransferase, Bicarbonate, Calcium, Potassium

    The table represents the percentage of participants in each group with normal baseline values and markedly abnormal end-of-stimulation or end-of-cycle visit values for alanine aminotransferase, aspartate aminotransferase, bicarbonate, calcium, potassium. Data in this endpoint are presented for the fresh cycle.

    Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)

  56. Proportion of Subjects With Markedly Abnormal Changes of Haematology Parameters: Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Neutrophils/Leukocytes

    The table represents the percentage of participants in each group with normal baseline values and markedly abnormal end-of-stimulation or end-of-cycle visit values for Leukocytes, eosinophils/leukocytes, lymphocytes/leukocytes and neutrophils/leukocytes. Data in this endpoint are presented for the fresh cycle.

    Time frame: From screening (baseline) to the end-of-stimulation visit and end-of-cycle visit in the fresh cycle (approximately 6 months)

  57. Frequency and Intensity of Injection Site Reactions (Redness, Pain, Itching, Swelling and Bruising) Assessed by the Subject During the Stimulation Period

    Assessed by the participant during the stimulation period. Participants assessed the injection site reactions (redness, pain, itching, swelling and bruising) three times daily: immediately after the injection, 30 minutes after the injection and 24 hours after the injection.

    Time frame: End-of-stimulation (up to 20 stimulation days)

  58. Intensity of Injection Site Reactions (Redness, Pain, Itching, Swelling and Bruising) Assessed by the Subject During the Stimulation Period

    Assessed by the participant during the stimulation period as mild, moderate or severe.

    Time frame: End-of-stimulation (up to 20 stimulation days)

  59. Proportion of Subjects With Treatment-induced Anti-FSH Antibodies, Overall as Well as With Neutralizing Capacity

    Measured by presence of anti-FSH antibodies. 95% Clopper-Pearson confidence interval has been reported in this endpoint.

    Time frame: Up to 28 days after end of the stimulation period

  60. Frequency and Intensity of Immune-related Adverse Events

    Standardised Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQs).

    Time frame: From time of signing informed consent for participation in the trial until the end-of-cycle visit in the fresh cycle (approximately 6 months)

  61. Proportion of Subjects With Cycle Cancellations Due to an Adverse Event, Including Immune-related Adverse Events, or Due to Technical Malfunctions of the Administration Pen

    For each participant the reason for cycle cancellation will be recorded. Data in this endpoint are presented for the fresh cycle.

    Time frame: Up to 20 stimulation days

  62. Proportion of Subjects With OHSS, Overall and by Grade, and Proportion of Subjects With Moderate/Severe OHSS

    Classification of grade was according to Golan's classification system, and all OHSS cases were graded as mild, moderate or severe. Data in this endpoint are presented for the fresh cycle.

    Time frame: ≤9 days after triggering of final follicular maturation (early OHSS), >9 days after triggering of final follicular maturation until 21-28 days after last IMP dose or up to ongoing pregnancy 8-9 weeks after transfer in pregnant participants (late OHSS)

  63. Proportion of Subjects Hospitalized Due to OHSS and Proportion of Subjects Undergoing Paracentesis Due to OHSS

    Percentage of participants hospitalized or undergoing paracentesis due to OHSS are reported

    Time frame: ≤9 days after triggering of final follicular maturation (early OHSS), >9 days after triggering of final follicular maturation until 21-28 days after last IMP dose or up to ongoing pregnancy 8-9 weeks after transfer in pregnant participants (late OHSS)

  64. Proportion of Participants With Multi-fetal Gestation in the Fresh Cycle

    Defined as pregnancy with more than one fetus. Among participants with ongoing pregnancy, percentage of participants with twin pregnancies are presented. '%' in the unit of measure refers to 'percentage'.

    Time frame: Up to 8-9 weeks after transfer

  65. Proportion of Cryopreserved Cycles With Multi-fetal Gestation

    Defined as pregnancy with more than one fetus. Among cryopreserved cycles with ongoing pregnancy, percentage of cycles with twin pregnancies are presented. '%' in the unit of measure refers to 'percentage'.

    Time frame: Up to 8-9 weeks after transfer

  66. Biochemical Pregnancy, Spontaneous Abortion, Ectopic Pregnancy (With and Without Medical/Surgical Intervention) and Vanishing Twins in the Fresh Cycle

    The percentage of participants with biochemical pregnancy, spontaneous abortion, ectopic pregnancy (with and without medical/surgical intervention) and vanishing twins in the fresh cycle are presented. Data represents participants with positive βhCG. Data is not shown for placebo arm because no participants had a positive βhCG. '%' in the unit of measure refers to 'percentage'. Unit: % of participants with early pregnancy loss.

    Time frame: Up to 8-9 weeks after transfer

  67. Biochemical Pregnancy, Spontaneous Abortion, Ectopic Pregnancy (With and Without Medical/Surgical Intervention) and Vanishing Twins in the Cryopreserved Cycles

    The percentage of cryopreserved cycles with biochemical pregnancy, spontaneous abortion, ectopic pregnancy (with and without medical/surgical intervention) and vanishing twins are presented. Data is not shown for placebo arm because no participants had a positive βhCG. '%' in the unit of measure refers to 'percentage'.

    Time frame: Up to 8-9 weeks after transfer

  68. Proportion of Participants With Technical Malfunctions of the Administration Pen

    Incidences of technical malfunctions of the administration pen were recorded.

    Time frame: Up to 20 stimulation days

07

Results

Posted Jan 18, 2024

Participant flow

The trial was performed in 24 investigational sites in 18 states of the United States between Oct 2018 to Dec 2020.

Participant flow — Overall Study
MilestoneFE 999049 (Follitropin Delta)Placebo
Started53454
Modified intention-to-treat (mitt)53354
Completed50254
Not completed320
Withdrew: Protocol deviation230
Withdrew: Adverse event40
Withdrew: Lost to follow-up20
Withdrew: Randomization failure10
Withdrew: Participant relocated, unable to continue in trial10
Withdrew: Participant did not show to visit (stimulation day 12)10

Outcome measures

PrimaryCumulative Ongoing Pregnancy Rate After the Fresh Cycle and Cryopreserved Cycles Initiated Within 12 Months From the Start of Controlled Ovarian Stimulation (COS)

Defined as at least one intrauterine viable fetus 8-9 weeks after transfer. Data in this endpoint are presented for the fresh cycle and the cryopreserved cycles.

Time frame:
8-9 weeks after transfer (up to approximately 16 months after start of stimulation)
Reported as:
Number · percentage of participants
Cumulative Ongoing Pregnancy Rate After the Fresh Cycle and Cryopreserved Cycles Initiated Within 12 Months From the Start of Controlled Ovarian Stimulation (COS)
percentage of participantsFE 999049 (Follitropin Delta)Placebo
Cumulative Ongoing Pregnancy Rate After the Fresh Cycle and Cryopreserved Cycles Initiated Within 12 Months From the Start of Controlled Ovarian Stimulation (COS)43.30.0
Statistical analysis
  • FE 999049 (Follitropin Delta) vs Placebo · Fisher Exact · p = <0.001 · Treatment difference: 43.3 · 95% CI 36.5 to 47.695% exact Agresti-Min confidence intervals.
SecondaryOngoing Pregnancy Rate in the Fresh Cycle and in the Cryopreserved Cycles

Defined as at least one intrauterine viable fetus 8-9 weeks after transfer. Data in this endpoint are presented for the fresh cycle and the cryopreserved cycles.

Time frame:
8-9 weeks after transfer (up to approximately 16 months after start of stimulation)
Reported as:
Number · percentage of participants
Ongoing Pregnancy Rate in the Fresh Cycle and in the Cryopreserved Cycles
percentage of participantsFE 999049 (Follitropin Delta)Placebo
Fresh cycle22.00.0
Cryopreserved cycles47.80
Statistical analysis
  • FE 999049 (Follitropin Delta) vs Placebo · Fisher Exact · p = <0.001 · Treatment difference: 22.0 · 95% CI 14.9 to 25.795% exact Agresti-Min confidence intervals.
SecondaryTime From Start of COS to Ongoing Pregnancy Across the Fresh and Cryopreserved Cycles, Including Duration

Time from start of COS to ongoing pregnancy, including both the fresh and cryopreserved cycles. In the placebo group, no participants achieved an ongoing pregnancy either after 12 calendar months or after 12 study months.

Time frame:
8-9 weeks after transfer (up to approximately 16 months after start of stimulation)
Reported as:
Mean · days
Time From Start of COS to Ongoing Pregnancy Across the Fresh and Cryopreserved Cycles, Including Duration
daysFE 999049 (Follitropin Delta)
Total number of days until ongoing pregnancy 12 study months134.7 ± 87.2
Total number of days until ongoing pregnancy 12 calendar months130.1 ± 77.8
SecondaryTime From Start of COS to Ongoing Pregnancy Across the Fresh and Cryopreserved Cycles, Measured in Number of Cycles Before Achieving Ongoing Pregnancy

Time from start of COS to ongoing pregnancy, including both the fresh and cryopreserved cycles, measured in number of cycles before achieving ongoing pregnancy. In the placebo group, no participants achieved an ongoing pregnancy either after 12 calendar months or after 12 study months.

Time frame:
8-9 weeks after transfer (up to approximately 16 months after start of stimulation)
Reported as:
Mean · Cycles
Time From Start of COS to Ongoing Pregnancy Across the Fresh and Cryopreserved Cycles, Measured in Number of Cycles Before Achieving Ongoing Pregnancy
CyclesFE 999049 (Follitropin Delta)
Number of cycles until ongoing pregnancy 12 study months1.8 ± 1.0
Number of cycles until ongoing pregnancy 12 calendar months1.7 ± 1.0
SecondaryOngoing Implantation Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively

Defined as the number of intrauterine viable fetuses 8-9 weeks after transfer divided by number of blastocysts transferred. Data in this endpoint are presented for the fresh cycle, the cryopreserved cycles, and all cycles. One participant can contribute with a range from zero to multiple blastocysts. Data is not shown for placebo arm because no subjects underwent blastocyst transfer in the fresh cycle or cryopreserved cycles. '%' in the unit of measure refers to 'percentage'.

Time frame:
8-9 weeks after transfer (up to approximately 16 months after start of stimulation)
Reported as:
Number · % of viable fetus/blastocyst transfer
Ongoing Implantation Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively
% of viable fetus/blastocyst transferFE 999049 (Follitropin Delta)
Fresh cycle32.7
Cryopreserved cycles30.6
All cycles31.6
SecondaryClinical Pregnancy Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively

Defined at least one gestational sac 5-6 weeks after transfer. Data in this endpoint are presented for the fresh cycle, the cryopreserved cycles, and all cycles.

Time frame:
5-6 weeks after transfer (up to approximately 15 months after start of stimulation)
Reported as:
Number · percentage of participants
Clinical Pregnancy Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively
percentage of participantsFE 999049 (Follitropin Delta)Placebo
Fresh cycle26.80.0
Cryopreserved cycles58.00
All cycles52.00.0
Statistical analysis
  • FE 999049 (Follitropin Delta) vs Placebo · Fisher Exact · p = <0.001 · Treatment difference: 26.8 · 95% CI 19.8 to 30.895% exact Agresti-Min confidence intervals.
  • FE 999049 (Follitropin Delta) vs Placebo · Fisher Exact · p = <0.001 · Treatment difference: 52.0 · 95% CI 44.9 to 56.395% exact Agresti-Min confidence intervals.
SecondaryVital Pregnancy Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively

Defined at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after transfer. Data in this endpoint are presented for the fresh cycle, the cryopreserved cycles, and all cycles.

Time frame:
5-6 weeks after transfer (up to approximately 15 months after start of stimulation)
Reported as:
Number · percentage of participants
Vital Pregnancy Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively
percentage of participantsFE 999049 (Follitropin Delta)Placebo
Fresh cycle23.50.0
Cryopreserved cycles49.40
All cycles45.60.0
Statistical analysis
  • FE 999049 (Follitropin Delta) vs Placebo · Fisher Exact · p = <0.001 · Treatment difference: 23.5 · 95% CI 16.7 to 27.295% exact Agresti-Min confidence intervals.
  • FE 999049 (Follitropin Delta) vs Placebo · Fisher Exact · p = <0.001 · Treatment difference: 45.6 · 95% CI 38.5 to 49.995% exact Agresti-Min confidence intervals.
SecondaryImplantation Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively

Defined as the number of gestational sacs 5-6 weeks after transfer divided by number of blastocysts transferred. The endpoint are presented for the fresh cycle, the cryopreserved cycles, and all cycles. One participant can contribute with a range from zero to multiple blastocysts. Data is not shown for placebo arm because no subjects underwent blastocyst transfer in the fresh cycle or cryopreserved cycles. '%' in the unit of measure refers to 'percentage'.

Time frame:
5-6 weeks after transfer (up to approximately 15 months after start of stimulation)
Reported as:
Number · % gestational sacs/blastocyst transfer
Implantation Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively
% gestational sacs/blastocyst transferFE 999049 (Follitropin Delta)
Fresh cycle40.4
Cryopreserved cycles40.2
All cycles40.3
SecondaryPositive Beta Human Chorionic Gonadotropin (βhCG) Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively

Defined as positive serum βhCG test 10-14 days after transfer. Data in this endpoint are presented for the fresh cycle, the cryopreserved cycles, and all cycles.

Time frame:
10-14 days after transfer (up to approximately 14 months after start of stimulation)
Reported as:
Number · percentage of participants
Positive Beta Human Chorionic Gonadotropin (βhCG) Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively
percentage of participantsFE 999049 (Follitropin Delta)Placebo
Fresh cycle32.10.0
Cryopreserved cycles65.30
All cycles58.90.0
Statistical analysis
  • FE 999049 (Follitropin Delta) vs Placebo · Fisher Exact · p = <0.001 · Treatment difference: 32.1 · 95% CI 24.9 to 36.295% exact Agresti-Min confidence intervals.
  • FE 999049 (Follitropin Delta) vs Placebo · Fisher Exact · p = <0.001 · Treatment difference: 58.9 · 95% CI 51.9 to 63.095% exact Agresti-Min confidence intervals.
SecondaryProportion of Subjects in the Fresh Cycle With Triggering of Final Follicular Maturation (With hCG, With GnRH Agonist, and in Total), Cycle Cancellation and Transfer Cancellation

Data in this endpoint are presented for the fresh cycle.

Time frame:
Up to 5 days after oocyte retrieval (up to 27 days after start of stimulation)
Reported as:
Number · percentage of participants
Proportion of Subjects in the Fresh Cycle With Triggering of Final Follicular Maturation (With hCG, With GnRH Agonist, and in Total), Cycle Cancellation and Transfer Cancellation
percentage of participantsFE 999049 (Follitropin Delta)Placebo
Triggering drug (hCG)79.51.9
Triggering drug (GnRH agonist)15.00.0
Triggering drug (None)5.498.1
Cycle cancellation5.498.1
Transfer cancellation31.51.9
SecondaryNumber of Follicles on Stimulation Day 5

The total number of follicles and the number of follicles per size category are reported.

Time frame:
On stimulation day 5
Reported as:
Mean · number of follicles
Number of Follicles on Stimulation Day 5
number of folliclesFE 999049 (Follitropin Delta)Placebo
Total number of follicles14.8 ± 8.412.5 ± 8.0
Follicles >= 12 mm1.7 ± 1.80.4 ± 0.6
Follicles >= 17 mm0.0 ± 0.20.0 ± 0.2
SecondaryNumber of Follicles at End-of-stimulation

The total number of follicles and the number of follicles per size category are reported.

Time frame:
At end-of-stimulation (up to 20 stimulation days)
Reported as:
Mean · number of follicles
Number of Follicles at End-of-stimulation
number of folliclesFE 999049 (Follitropin Delta)Placebo
Total number of follicles17.4 ± 10.013.6 ± 9.5
Follicles >= 12 mm10.1 ± 6.30.8 ± 0.7
Follicles >= 17 mm3.6 ± 2.30.4 ± 0.5
SecondarySize of Follicles on Stimulation Day 5

Counted by ultrasound for the right and left ovary for each participant.

Time frame:
On stimulation day 5
Reported as:
Mean · mm
Size of Follicles on Stimulation Day 5
mmFE 999049 (Follitropin Delta)Placebo
Largest follicle (mm)12.4 ± 2.310.8 ± 2.5
Average size of 2 largest follicles (mm)11.8 ± 2.19.8 ± 1.9
SecondarySize of Follicles at End-of-stimulation

Counted by ultrasound for the right and left ovary for each participant.

Time frame:
At end-of-stimulation (up to 20 stimulation days)
Reported as:
Mean · mm
Size of Follicles at End-of-stimulation
mmFE 999049 (Follitropin Delta)Placebo
Largest follicle (mm)19.8 ± 2.714.1 ± 5.1
Average size of 2 largest follicles (mm)18.9 ± 2.611.5 ± 3.3
SecondaryNumber of Oocytes Retrieved

The number of oocytes retrieved was recorded at the oocyte retrieval visit.

Time frame:
On day of oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Mean · number of oocytes retrieved
Number of Oocytes Retrieved
number of oocytes retrievedFE 999049 (Follitropin Delta)Placebo
Number of Oocytes Retrieved11.3 ± 8.90.0 ± 0.1
SecondaryProportion of Subjects With <4, 4-7, 8-14, 15-19 and ≥20 Oocytes Retrieved

Grouped according to the number of oocytes retrieved. Participants with cycle cancellation due to poor ovarian response are included in the \<4 oocytes group.

Time frame:
On day of oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Number · percentage of participants
Proportion of Subjects With <4, 4-7, 8-14, 15-19 and ≥20 Oocytes Retrieved
percentage of participantsFE 999049 (Follitropin Delta)Placebo
<4 oocytes retrieved14.6100
4-7 oocytes retrieved23.50
8-14 oocytes retrieved33.80
15-19 oocytes retrieved15.20
>=20 oocytes retrieved12.90
SecondaryNumber of Metaphase II Oocytes

The number of MII oocytes to oocytes retrieved for participants where all oocytes were inseminated using ICSI are presented.

Time frame:
On day of oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Mean · number of MII oocytes
Number of Metaphase II Oocytes
number of MII oocytesFE 999049 (Follitropin Delta)Placebo
Number of Metaphase II Oocytes8.8 ± 6.71.0 ± 0
SecondaryNumber of Fertilized Oocytes

An oocyte was defined as fertilized if it had 2 pronuclei (2PN) at 19h (±2h).

Time frame:
On day 1 after oocyte retrieval (up to 23 days after start of stimulation)
Reported as:
Mean · oocytes (number of fertilized oocytes)
Number of Fertilized Oocytes
oocytes (number of fertilized oocytes)FE 999049 (Follitropin Delta)Placebo
Number of Fertilized Oocytes6.4 ± 5.70.0 ± 0.1
SecondaryFertilization Rate

The fertilization rate was defined as the number of 2PN oocytes divided by the number of oocytes retrieved. Fertilization rate relative to oocytes retrieved has been reported.

Time frame:
On day 1 after oocyte retrieval (up to 23 days after start of stimulation)
Reported as:
Mean · percentage of fertilized oocytes
Fertilization Rate
percentage of fertilized oocytesFE 999049 (Follitropin Delta)Placebo
Fertilization Rate56.4 ± 23.3100.0 ± 0
SecondaryNumber and Quality of Blastocysts on Day 5 After Oocyte Retrieval

Number of blastocysts (total and good-quality) on Day 5 are presented. The quality evaluation of blastocysts consisted of assessment of three parameters, as per the Gardner \& Schoolcraft system: blastocyst expansion and hatching status (graded: 1-6), inner cell mass (graded: A-D) and trophectoderm (graded: A-D). A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher.

Time frame:
On day 5 after oocyte retrieval
Reported as:
Mean · blastocysts
Number and Quality of Blastocysts on Day 5 After Oocyte Retrieval
blastocystsFE 999049 (Follitropin Delta)Placebo
Number of blastocysts on day 53.7 ± 4.00.0 ± 0.0
Number of good-quality blastocysts on day 52.3 ± 3.00.0 ± 0.0
SecondaryEndometrial Thickness on Stimulation Day 5

Mean endometrial thickness is reported.

Time frame:
On stimulation day 5
Reported as:
Mean · mm
Endometrial Thickness on Stimulation Day 5
mmFE 999049 (Follitropin Delta)Placebo
Endometrial Thickness on Stimulation Day 58.0 ± 2.16.2 ± 1.9
Statistical analysis
  • FE 999049 (Follitropin Delta) vs Placebo · Wilcoxon rank sum test · p = <0.001
SecondaryEndometrial Thickness at End-of-stimulation

Mean endometrial thickness is reported.

Time frame:
At end-of-stimulation (up to 20 stimulation days)
Reported as:
Mean · mm
Endometrial Thickness at End-of-stimulation
mmFE 999049 (Follitropin Delta)Placebo
Endometrial Thickness at End-of-stimulation10.6 ± 2.57.8 ± 2.3
Statistical analysis
  • FE 999049 (Follitropin Delta) vs Placebo · Wilcoxon rank sum test · p = <0.001
SecondaryEchogenicity Pattern on Stimulation Day 5

The distribution of participants with hypoechogenic, isoechogenic, or hyperechogenic endometrium is reported

Time frame:
On stimulation day 5
Reported as:
Number · percentage of participants
Echogenicity Pattern on Stimulation Day 5
percentage of participantsFE 999049 (Follitropin Delta)Placebo
Hypoechogenic64.257.4
Isoechogenic6.45.6
Hyperechogenic28.733.3
Not possible to evaluate0.83.7
Statistical analysis
  • FE 999049 (Follitropin Delta) vs Placebo · Fisher Exact · p = 0.190
SecondaryEchogenicity Pattern at End-of-stimulation

The distribution of participants with hypoechogenic, isoechogenic, or hyperechogenic endometrium is reported.

Time frame:
At end-of-stimulation (up to 20 stimulation days)
Reported as:
Number · percentage of participants
Echogenicity Pattern at End-of-stimulation
percentage of participantsFE 999049 (Follitropin Delta)Placebo
Hypoechogenic68.068.5
Isoechogenic3.23.7
Hyperechogenic28.425.9
Not possible to evaluate0.41.9
Statistical analysis
  • FE 999049 (Follitropin Delta) vs Placebo · Fisher Exact · p = 0.396
SecondaryOocyte Utilization Rate

Defined as the number of blastocysts transferred or cryopreserved divided by the number of oocytes retrieved. Data in this endpoint are presented for the cryopreserved cycles.

Time frame:
On day of oocyte retrieval up to 12 months after start of COS
Reported as:
Mean · blastocysts/oocyte retrieved
Oocyte Utilization Rate
blastocysts/oocyte retrievedFE 999049 (Follitropin Delta)Placebo
Oocyte Utilization Rate30.6 ± 21.20.0 ± 0
SecondaryOocyte Efficiency Index

Defined as the cumulative number of ongoing pregnancies per oocyte retrieved. Data in this endpoint are presented for the cryopreserved cycles. The unit of measure for this endpoint is 'cumulative ongoing pregnancies/oocyte retrieved'.

Time frame:
8-9 weeks after transfer
Reported as:
Mean · ongoing pregnancies/oocyte retrieved
Oocyte Efficiency Index
ongoing pregnancies/oocyte retrievedFE 999049 (Follitropin Delta)Placebo
Oocyte Efficiency Index4.5 ± 6.40.0 ± 0
SecondaryPercentage of Blastocysts Surviving Cryopreservation

Data in this endpoint are presented for the cryopreserved cycles. The unit is number of blastocysts with observations. One participant can contribute with a range from zero to multiple blastocysts.

Time frame:
0 hour (+0.5 hour) after thawing
Reported as:
Number · percentage of blastocysts
Percentage of Blastocysts Surviving Cryopreservation
percentage of blastocystsFE 999049 (Follitropin Delta)
Percentage of Blastocysts Surviving Cryopreservation98.5
SecondaryPercentage of Blastocysts With Re-expansion After Cryopreservation

Data in this endpoint are presented for the cryopreserved cycles. The unit is number of blastocysts with observations. One participant can contribute with a range from zero to multiple blastocysts.

Time frame:
2.5 hour (±0.5 hour) after thawing
Reported as:
Number · percentage of blastocysts
Percentage of Blastocysts With Re-expansion After Cryopreservation
percentage of blastocystsFE 999049 (Follitropin Delta)
Percentage of Blastocysts With Re-expansion After Cryopreservation97.2
SecondaryNumber of Cryopreserved Cycles Initiated Within 12 Months From the Start of COS

The total number of cryopreserved cycles initiated are reported. Data in this endpoint are presented for the cryopreserved cycles. One participant can contribute with a range from zero to multiple blastocysts.

Time frame:
Up to 12 months after start of stimulation
Reported as:
Number · Percentages of cycles
Number of Cryopreserved Cycles Initiated Within 12 Months From the Start of COS
Percentages of cyclesFE 999049 (Follitropin Delta)
Programmed cycles initiated92.1
Natural cycles initiated7.9
SecondaryNumber of Cryopreserved Cycles With Blastocyst Transfer

The total number of cryopreserved cycles with blastocyst transfer are reported. Data in this endpoint are presented for the cryopreserved cycles. One participant can contribute with a range from zero to multiple blastocysts.

Time frame:
Up to 12 months after start of stimulation
Reported as:
Number · Percentages of cycles
Number of Cryopreserved Cycles With Blastocyst Transfer
Percentages of cyclesFE 999049 (Follitropin Delta)
Programmed cycles with transfer92.8
Natural cycles with transfer7.2
SecondaryCirculating Concentrations of Anti-mullerian Hormone (AMH)

Blood samples for analysis of circulating concentrations of AMH were drawn. The median and inter-quartile range (IQR) of AMH levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.

Time frame:
From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Median · pmol/L
Circulating Concentrations of Anti-mullerian Hormone (AMH)
pmol/LFE 999049 (Follitropin Delta)Placebo
Stimulation day 113.2 (7.2 to 20.9)11.3 (6.7 to 18.3)
Stimulation day 510.9 (5.6 to 17.5)13.1 (6.6 to 19.6)
End-of-stimulation visit6.4 (3.6 to 10.5)14.6 (7.0 to 21.5)
Oocyte retrieval visit5.0 (2.9 to 8.0)—
SecondaryCirculating Concentrations of Follicle-stimulating Hormone (FSH)

Blood samples for analysis of circulating concentrations of FSH were drawn. The median and IQR of FSH levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.

Time frame:
From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Median · IU/L
Circulating Concentrations of Follicle-stimulating Hormone (FSH)
IU/LFE 999049 (Follitropin Delta)Placebo
Stimulation day 18.7 (7.4 to 10.6)8.9 (7.4 to 10.5)
Stimulation day 520.5 (16.3 to 24.8)7.8 (6.3 to 9.4)
End-of-stimulation visit24.8 (20.2 to 30.3)7.1 (6.2 to 9.6)
Oocyte retrieval visit14.8 (12.4 to 17.8)20.2 (20.2 to 20.2)
SecondaryCirculating Concentrations of Luteinizing Hormone (LH)

Blood samples for analysis of circulating concentrations of LH were drawn. The median and IQR of LH levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.

Time frame:
From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Median · IU/L
Circulating Concentrations of Luteinizing Hormone (LH)
IU/LFE 999049 (Follitropin Delta)Placebo
Stimulation day 14.8 (3.7 to 6.3)5.0 (3.6 to 6.6)
Stimulation day 52.4 (1.6 to 3.7)5.7 (4.3 to 7.3)
End-of-stimulation visit2.0 (1.3 to 3.3)8.8 (6.5 to 14.7)
Oocyte retrieval visit2.2 (1.2 to 3.7)28.1 (28.1 to 28.1)
SecondaryCirculating Concentrations of Estradiol

Blood samples for analysis of circulating concentrations of estradiol were drawn. The median and IQR of estradiol levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.

Time frame:
From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Median · pg/mL
Circulating Concentrations of Estradiol
pg/mLFE 999049 (Follitropin Delta)Placebo
Stimulation day 141.2 (33.7 to 52.6)40.2 (34.0 to 48.9)
Stimulation day 5383.6 (235.1 to 599.6)59.0 (45.4 to 89.4)
End-of-stimulation visit1471.0 (891.0 to 2292.5)109.6 (52.0 to 174.6)
Oocyte retrieval visit745.1 (439.4 to 1177.3)107.4 (107.4 to 107.4)
SecondaryCirculating Concentrations of Progesterone

Blood samples for analysis of circulating concentrations of progesterone were drawn. The median and IQR of progesterone levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.

Time frame:
From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Median · ng/mL
Circulating Concentrations of Progesterone
ng/mLFE 999049 (Follitropin Delta)Placebo
Stimulation day 10.5 (0.3 to 0.7)0.5 (0.3 to 0.7)
Stimulation day 50.6 (0.3 to 0.8)0.3 (0.3 to 0.5)
End-of-stimulation visit1.1 (0.7 to 1.5)0.3 (0.3 to 0.6)
Oocyte retrieval visit6.2 (4.3 to 8.9)2.0 (2.0 to 2.0)
SecondaryCirculating Concentrations of Inhibin A

Blood samples for analysis of circulating concentrations of inhibin A were drawn. The median and IQR of inhibin A levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.

Time frame:
From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Median · pg/mL
Circulating Concentrations of Inhibin A
pg/mLFE 999049 (Follitropin Delta)Placebo
Stimulation day 15.3 (3.8 to 7.0)5.8 (4.3 to 7.0)
Stimulation day 570.3 (42.2 to 103.2)8.7 (6.0 to 12.1)
End-of-stimulation visit258.7 (159.6 to 379.8)19.8 (8.0 to 35.4)
Oocyte retrieval visit204.3 (136.9 to 287.1)—
SecondaryCirculating Concentrations of Inhibin B

Blood samples for analysis of circulating concentrations of inhibin B were drawn. The median and IQR of inhibin B levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.

Time frame:
From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Median · pg/mL
Circulating Concentrations of Inhibin B
pg/mLFE 999049 (Follitropin Delta)Placebo
Stimulation day 175.0 (52.0 to 99.0)79.0 (51.0 to 99.0)
Stimulation day 5517.0 (301.0 to 828.0)93.5 (77.0 to 112.0)
End-of-stimulation visit671.0 (356.0 to 1039.0)64.5 (51.0 to 97.0)
Oocyte retrieval visit301.5 (173.0 to 463.0)—
SecondaryTotal Gonadotropin Dose

Calculated by start dates, end dates and daily dose of IMP.

Time frame:
Up to 20 stimulation days
Reported as:
Mean · microgram of dose
Total Gonadotropin Dose
microgram of doseFE 999049 (Follitropin Delta)Placebo
Total Gonadotropin Dose131.2 ± 30.8146.5 ± 20.4
SecondaryNumber of Stimulation Days

Calculated by start dates and end dates.

Time frame:
Up to 20 stimulation days
Reported as:
Mean · days
Number of Stimulation Days
daysFE 999049 (Follitropin Delta)Placebo
Number of Stimulation Days8.2 ± 1.48.5 ± 0.9
SecondaryProportion of Participants With Investigator-requested Gonadotropin Dose Adjustments

Investigator-requested decreases and increases of the gonadotropin dose.

Time frame:
Stimulation Day 5
Reported as:
Number · percentage of participants
Proportion of Participants With Investigator-requested Gonadotropin Dose Adjustments
percentage of participantsFE 999049 (Follitropin Delta)Placebo
Decrease6.20
No change50.713.0
Increase43.287.0
SecondaryPercentage of Participants With Adverse Events (AEs)

Any AE occurring after start of IMP and before the end-of-trial visit, or a pre-treatment AE or pre-existing medical condition that worsens in intensity after start of IMP and before the end-of-trial visit was considered treatment-emergent, and is presented for this endpoint. Data in this endpoint are presented for the fresh cycle.

Time frame:
From time of signing informed consent until the end-of-cycle visit in the fresh cycle (approximately 6 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs)
percentage of participantsFE 999049 (Follitropin Delta)Placebo
Percentage of Participants With Adverse Events (AEs)49.913.0
SecondaryIntensity of AEs

The intensity of AE was classified using the following 3-point scale: mild = awareness of signs or symptoms, but no disruption of usual activity; moderate = event sufficient to affect usual activity (disturbing); or severe = inability to work or perform usual activities (unacceptable). Data in this endpoint are presented for the fresh cycle.

Time frame:
From time of signing informed consent until the end-of-cycle visit in the fresh cycle (up to approximately 6 months)
Reported as:
Number · percentage of participants
Intensity of AEs
percentage of participantsFE 999049 (Follitropin Delta)Placebo
Mild AEs44.511.1
Moderate AEs15.45.6
Severe AEs0.90
SecondaryChanges in Circulating Levels of Clinical Chemistry Compared to Baseline: Albumin, Protein

Blood samples were collected for the analysis of clinical chemistry parameters including: Albumin and protein. Data in this endpoint are presented for the fresh cycle.

Time frame:
From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Reported as:
Mean · g/L
Changes in Circulating Levels of Clinical Chemistry Compared to Baseline: Albumin, Protein
g/LFE 999049 (Follitropin Delta)Placebo
Albumin (End-of-stimulation visit)-1.53 ± 2.450.18 ± 2.12
Albumin (End-of-cycle visit)-1.90 ± 2.75-0.65 ± 2.29
Protein (End-of-stimulation visit)-2.76 ± 3.98-0.17 ± 3.45
Protein (End-of-cycle visit)-1.92 ± 4.12-0.96 ± 3.55
SecondaryChanges in Circulating Levels of Clinical Chemistry Compared to Baseline: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase and Gamma Glutamyl Transferase

Blood samples were collected for the analysis of clinical chemistry parameters including: Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase and gamma glutamyl transferase. Data in this endpoint are presented for the fresh cycle.

Time frame:
From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Reported as:
Mean · IU/L
Changes in Circulating Levels of Clinical Chemistry Compared to Baseline: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase and Gamma Glutamyl Transferase
IU/LFE 999049 (Follitropin Delta)Placebo
Alanine aminotransferase (End-of-stimulation visit)0.3 ± 10.42.3 ± 18.9
Alanine aminotransferase (End-of-cycle visit)-0.7 ± 9.0-2.3 ± 18.0
Alkaline phosphatase (End-of-stimulation visit)-1.3 ± 7.21.6 ± 6.2
Alkaline phosphatase (End-of-cycle visit)-0.6 ± 9.6-0.9 ± 6.7
Aspartate aminotransferase (Endof-stimulation visit)0.2 ± 8.62.0 ± 8.6
Aspartate aminotransferase (End-of- cycle visit)-0.9 ± 6.2-0.5 ± 6.4
Gamma glutamy transferase (End-of-stimulation visit)-1.5 ± 8.3-0.6 ± 6.5
Gamma glutamyl transferase (End-of-cycle visit)-1.0 ± 11.8-1.0 ± 8.2
SecondaryChanges in Circulating Levels of Clinical Chemistry Compared to Baseline: Bicarbonate, Blood Urea Nitrogen, Calcium, Chloride, Cholesterol, Glucose, Phosphate, Potassium and Sodium

Blood samples were collected for the analysis of clinical chemistry parameters including: Bicarbonate, blood urea nitrogen, calcium, chloride, cholesterol, glucose, Phosphate, Potassium and Sodium. Data in this endpoint are presented for the fresh cycle.

Time frame:
From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Reported as:
Mean · mmol/L
Changes in Circulating Levels of Clinical Chemistry Compared to Baseline: Bicarbonate, Blood Urea Nitrogen, Calcium, Chloride, Cholesterol, Glucose, Phosphate, Potassium and Sodium
mmol/LFE 999049 (Follitropin Delta)Placebo
Bicarbonate (End-of-stimulation visit)-0.05 ± 2.240.56 ± 2.22
Bicarbonate (End-of-cycle visit)-0.91 ± 2.42-0.47 ± 2.38
Blood urea nitrogen (End-of-stimulation visit)-0.2 ± 1.1-0.1 ± 1.1
Blood urea nitrogen (End-of-cycle visit)-0.3 ± 1.10.0 ± 1.1
Calcium (End-of-stimulation visit)-0.02 ± 0.080.02 ± 0.09
Calcium (End-of-cycle visit)-0.02 ± 0.09-0.01 ± 0.09
Chloride (End-of-stimulation visit)-0.6 ± 2.30.3 ± 2.1
Chloride (End-of-cycle visit)0.4 ± 2.40.9 ± 2.3
Cholesterol (End-of-stimulation visit)-0.4 ± 0.50.0 ± 0.5
Cholesterol (End-of-cycle visit)0.1 ± 0.6-0.1 ± 0.6
Glucose (End-of-stimulation visit)-0.1 ± 0.90.2 ± 0.9
Glucose (End-of-cycle visit)0.0 ± 0.90.2 ± 1.1
Phosphate (End-of stimulation visit)-0.04 ± 0.160.03 ± 0.13
Phosphate (End-of-cycle visit)0.01 ± 0.180.00 ± 0.18
Potassium (End-of-stimulation visit)0.00 ± 0.440.19 ± 0.40
Potassium (End-of-cycle visit)0.09 ± 0.470.25 ± 0.46
Sodium (End-of-stimulation visit)-0.6 ± 2.40.9 ± 2.5
Sodium (End-of-cycle visit)-0.4 ± 2.80.5 ± 2.5
SecondaryChanges in Circulating Levels of Clinical Chemistry Compared to Baseline: Direct Bilirubin, Total Bilirubin, Creatinine, Urate

Blood samples were collected for the analysis of clinical chemistry parameters including: Direct bilirubin, total bilirubin, creatinine, urate. Data in this endpoint are presented for the fresh cycle.

Time frame:
From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Reported as:
Mean · umol/L
Changes in Circulating Levels of Clinical Chemistry Compared to Baseline: Direct Bilirubin, Total Bilirubin, Creatinine, Urate
umol/LFE 999049 (Follitropin Delta)Placebo
Direct bilirubin (End-of-stimulation visit)-0.09 ± 0.94-0.26 ± 0.82
Direct bilirubin (End-of-cycle visit)-0.28 ± 0.96-0.08 ± 0.92
Total bilirubin (End-of-stimulation visit)-0.58 ± 3.50-0.56 ± 3.92
Total bilirubin (End-of-cycle visit)-0.99 ± 3.640.23 ± 3.82
Creatinine (End-of-stimulation visit)-3.99 ± 7.48-0.18 ± 8.65
Creatinine (End-of-cycle visit)-3.47 ± 9.550.85 ± 7.27
Urate (End-of-stimulation visit)-1.13 ± 36.24-5.08 ± 36.99
Urate (End-of-cycle visit)-10.53 ± 48.586.06 ± 42.05
SecondaryChanges in Circulating Levels of Clinical Chemistry Compared to Baseline: Lactate Dehydrogenase

Blood samples were collected for the analysis of clinical chemistry parameters including: Lactate dehydrogenase. Data in this endpoint are presented for the fresh cycle.

Time frame:
From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Reported as:
Mean · U/L
Changes in Circulating Levels of Clinical Chemistry Compared to Baseline: Lactate Dehydrogenase
U/LFE 999049 (Follitropin Delta)Placebo
End-of-stimulation visit-12.0 ± 18.5-3.8 ± 14.3
End-of-cycle visit-0.4 ± 20.7-0.8 ± 16.8
SecondaryChanges in Haematology Parameters Compared to Baseline: Erythrocytes

Blood samples were collected for the analysis of haematology parameter including: Erythrocytes. Data in this endpoint are presented for the fresh cycle.

Time frame:
From screening to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Reported as:
Mean · 10^12 cells/L
Changes in Haematology Parameters Compared to Baseline: Erythrocytes
10^12 cells/LFE 999049 (Follitropin Delta)Placebo
End-of-stimulation visit-0.13 ± 0.23-0.03 ± 0.23
End-of-cycle visit-0.15 ± 0.26-0.07 ± 0.23
SecondaryChanges in Haematology Parameters Compared to Baseline: Haemoglobin

Blood samples were collected for the analysis of haematology parameters including: Haemoglobin. Data in this endpoint are presented for the fresh cycle.

Time frame:
From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Reported as:
Mean · g/L
Changes in Haematology Parameters Compared to Baseline: Haemoglobin
g/LFE 999049 (Follitropin Delta)Placebo
End-of-stimulation visit-3.75 ± 6.60-0.20 ± 6.86
End-of-cycle visit-3.94 ± 7.64-1.76 ± 6.86
SecondaryChanges in Haematology Parameters Compared to Baseline: Haematocrit

Blood samples were collected for the analysis of haematology parameter including: Haematocrit. Data in this endpoint are presented for the fresh cycle.

Time frame:
From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Reported as:
Mean · ratio
Changes in Haematology Parameters Compared to Baseline: Haematocrit
ratioFE 999049 (Follitropin Delta)Placebo
End-of-stimulation visit0.0 ± 0.00.0 ± 0.0
End-of-cycle visit0.0 ± 0.00.0 ± 0.0
SecondaryChanges in Haematology Parameters Compared to Baseline: Erythrocyte Mean Corpuscular Volume

Blood samples were collected for the analysis of haematology parameter including: Erythrocyte mean corpuscular volume. Data in this endpoint are presented for the fresh cycle.

Time frame:
From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Reported as:
Mean · fL
Changes in Haematology Parameters Compared to Baseline: Erythrocyte Mean Corpuscular Volume
fLFE 999049 (Follitropin Delta)Placebo
End-of-stimulation visit1.4 ± 3.01.2 ± 3.2
End-of-cycle visit1.1 ± 3.11.4 ± 3.0
SecondaryChanges in Haematology Parameters Compared to Baseline: Leukocytes and Platelets

Blood samples were collected for the analysis of haematology parameters including: Leukocytes and platelets. Data in this endpoint are presented for the fresh cycle.

Time frame:
From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Reported as:
Mean · 10^9 cells/L
Changes in Haematology Parameters Compared to Baseline: Leukocytes and Platelets
10^9 cells/LFE 999049 (Follitropin Delta)Placebo
Leukocytes (End-of-stimulation visit)0.904 ± 1.913-0.822 ± 1.508
Leukocytes (End-of-cycle visit)0.357 ± 2.174-0.534 ± 1.636
Platelets (End-of-stimulation visit)-3.0 ± 41.0-2.0 ± 35.1
Platelets (End-of-cycle visit)9.5 ± 50.2-16.1 ± 42.1
SecondaryChanges in Haematology Parameters Compared to Baseline: Erythrocyte Mean Corpuscular Hemoglobin

Blood samples were collected for the analysis of haematology parameter including: Erythrocyte mean corpuscular haemoglobin. Data in this endpoint are presented for the fresh cycle.

Time frame:
From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Reported as:
Mean · picogram
Changes in Haematology Parameters Compared to Baseline: Erythrocyte Mean Corpuscular Hemoglobin
picogramFE 999049 (Follitropin Delta)Placebo
End-of-stimulation visit0.1 ± 0.80.1 ± 1.0
End-of-cycle visit0.1 ± 0.90.1 ± 0.8
SecondaryChanges in Haematology Parameters Compared to Baseline: Erythrocyte Mean Corpuscular Haemoglobin Concentration

Blood samples were collected for the analysis of haematology parameter including: Erythrocyte mean corpuscular haemoglobin concentration. Data in this endpoint are presented for the fresh cycle.

Time frame:
From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Reported as:
Mean · mmol/L
Changes in Haematology Parameters Compared to Baseline: Erythrocyte Mean Corpuscular Haemoglobin Concentration
mmol/LFE 999049 (Follitropin Delta)Placebo
End-of-stimulation visit-0.3 ± 0.8-0.2 ± 0.8
End-of-cycle visit-0.2 ± 0.8-0.3 ± 0.7
SecondaryChanges in Haematology Parameters Compared to Baseline: Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/Leukocytes and Neutrophils/Leukocytes

Blood samples were collected for the analysis of haematology parameters including: Basophils/leukocytes, eosinophils/ leukocytes, lymphocytes/leukocytes, monocytes/leukocytes and neutrophils/leukocytes. Data in this endpoint are presented for the fresh cycle.

Time frame:
From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Reported as:
Mean · percentage
Changes in Haematology Parameters Compared to Baseline: Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/Leukocytes and Neutrophils/Leukocytes
percentageFE 999049 (Follitropin Delta)Placebo
Basophils/leukocytes (End-of-stimulation visit)0.11 ± 0.520.10 ± 0.62
Basophils/leukocytes (End-of-cycle visit)0.07 ± 0.430.01 ± 0.55
Eosinophils/leukocytes (End-of-stimulation visit)-0.36 ± 1.250.03 ± 1.16
Eosinophils/leukocytes (End-of-cycle visit)-0.16 ± 1.350.04 ± 0.99
Lymphocytes/leukocytes (End-of-stimulation visit)-5.46 ± 6.730.59 ± 6.34
Lymphocytes/leukocytes (End-of-cycle visit)-1.27 ± 8.240.80 ± 5.39
Monocytes/leukocytes (End-of-stimulation visit)-0.44 ± 1.730.00 ± 1.74
Monocytes/leukocytes (End-of-cycle visit)0.14 ± 1.730.66 ± 1.80
Neutrophils/leukocytes (End-of-stimulation visit)6.14 ± 7.67-0.73 ± 7.40
Neutrophils/leukocytes (End-of-cycle visit)1.22 ± 9.09-1.51 ± 6.27
SecondaryProportion of Subjects With Markedly Abnormal Changes of Clinical Chemistry Parameters: Alanine Aminotransferase, Aspartate Aminotransferase, Bicarbonate, Calcium, Potassium

The table represents the percentage of participants in each group with normal baseline values and markedly abnormal end-of-stimulation or end-of-cycle visit values for alanine aminotransferase, aspartate aminotransferase, bicarbonate, calcium, potassium. Data in this endpoint are presented for the fresh cycle.

Time frame:
From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Reported as:
Number · percentage of participants
Proportion of Subjects With Markedly Abnormal Changes of Clinical Chemistry Parameters: Alanine Aminotransferase, Aspartate Aminotransferase, Bicarbonate, Calcium, Potassium
percentage of participantsFE 999049 (Follitropin Delta)Placebo
Alanine aminotransferase (End-of-stimulation visit)0.20.0
Aspartate aminotransferase (End-of-stimulation visit)0.20.0
Bicarbonate (End-of-stimulation visit)0.20.0
Calcium (End-of-stimulation visit)0.02.1
Glucose (End-of-stimulation visit)0.30.0
Potassium (End-of-stimulation visit)0.20.0
Alanine aminotransferase (End-of-cycle visit)0.20.0
Bicarbonate (End-of-cycle visit)0.20.0
SecondaryProportion of Subjects With Markedly Abnormal Changes of Haematology Parameters: Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Neutrophils/Leukocytes

The table represents the percentage of participants in each group with normal baseline values and markedly abnormal end-of-stimulation or end-of-cycle visit values for Leukocytes, eosinophils/leukocytes, lymphocytes/leukocytes and neutrophils/leukocytes. Data in this endpoint are presented for the fresh cycle.

Time frame:
From screening (baseline) to the end-of-stimulation visit and end-of-cycle visit in the fresh cycle (approximately 6 months)
Reported as:
Number · percentage of participants
Proportion of Subjects With Markedly Abnormal Changes of Haematology Parameters: Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Neutrophils/Leukocytes
percentage of participantsFE 999049 (Follitropin Delta)Placebo
Leukocytes (End-of-stimulation visit)0.20.0
Eosinophils/leukocytes (End-of-stimulation visit)0.20.0
Lymphocytes/leukocytes (End-of-stimulation visit)0.40.0
Neutrophils/leukocytes (End-of-stimulation visit)0.20.0
Leukocytes (End-of-cycle visit)0.60.0
Eosinophils/leukocytes (End-of-cycle visit)0.20.0
SecondaryFrequency and Intensity of Injection Site Reactions (Redness, Pain, Itching, Swelling and Bruising) Assessed by the Subject During the Stimulation Period

Assessed by the participant during the stimulation period. Participants assessed the injection site reactions (redness, pain, itching, swelling and bruising) three times daily: immediately after the injection, 30 minutes after the injection and 24 hours after the injection.

Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Number · percentage of events
Frequency and Intensity of Injection Site Reactions (Redness, Pain, Itching, Swelling and Bruising) Assessed by the Subject During the Stimulation Period
percentage of eventsFE 999049 (Follitropin Delta)Placebo
Frequency and Intensity of Injection Site Reactions (Redness, Pain, Itching, Swelling and Bruising) Assessed by the Subject During the Stimulation Period4.24.0
SecondaryIntensity of Injection Site Reactions (Redness, Pain, Itching, Swelling and Bruising) Assessed by the Subject During the Stimulation Period

Assessed by the participant during the stimulation period as mild, moderate or severe.

Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Number · percentage of events
Intensity of Injection Site Reactions (Redness, Pain, Itching, Swelling and Bruising) Assessed by the Subject During the Stimulation Period
percentage of eventsFE 999049 (Follitropin Delta)Placebo
Mild injection site reaction4.03.9
Moderate injection site reaction0.10.1
Severe injection site reaction0.01230.0147
SecondaryProportion of Subjects With Treatment-induced Anti-FSH Antibodies, Overall as Well as With Neutralizing Capacity

Measured by presence of anti-FSH antibodies. 95% Clopper-Pearson confidence interval has been reported in this endpoint.

Time frame:
Up to 28 days after end of the stimulation period
Reported as:
Number · percentage of participants
Proportion of Subjects With Treatment-induced Anti-FSH Antibodies, Overall as Well as With Neutralizing Capacity
percentage of participantsFE 999049 (Follitropin Delta)Placebo
Treatment-induced anti-FSH antibodies (Overall)0.75 (0.20 to 1.91)0.00 (0.00 to 6.60)
Treatment-induced anti-FSH antibodies with neutralizing capacity0 (NA to NA)0 (NA to NA)
SecondaryFrequency and Intensity of Immune-related Adverse Events

Standardised Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQs).

Time frame:
From time of signing informed consent for participation in the trial until the end-of-cycle visit in the fresh cycle (approximately 6 months)
Reported as:
Number · events
Frequency and Intensity of Immune-related Adverse Events
eventsFE 999049 (Follitropin Delta)Placebo
SMQ = Severe cutaneous adverse reactions30
SMQ = Anaphylactic reaction71
SMQ = Angioedema20
SMQ = Hypersensitivity131
Any general and local hypersensitivity reactions111
SecondaryProportion of Subjects With Cycle Cancellations Due to an Adverse Event, Including Immune-related Adverse Events, or Due to Technical Malfunctions of the Administration Pen

For each participant the reason for cycle cancellation will be recorded. Data in this endpoint are presented for the fresh cycle.

Time frame:
Up to 20 stimulation days
Reported as:
Number · percentage of participants
Proportion of Subjects With Cycle Cancellations Due to an Adverse Event, Including Immune-related Adverse Events, or Due to Technical Malfunctions of the Administration Pen
percentage of participantsFE 999049 (Follitropin Delta)Placebo
AE (including immune-related AEs)00
Technical malfunctions of the administration pen00
SecondaryProportion of Subjects With OHSS, Overall and by Grade, and Proportion of Subjects With Moderate/Severe OHSS

Classification of grade was according to Golan's classification system, and all OHSS cases were graded as mild, moderate or severe. Data in this endpoint are presented for the fresh cycle.

Time frame:
≤9 days after triggering of final follicular maturation (early OHSS), >9 days after triggering of final follicular maturation until 21-28 days after last IMP dose or up to ongoing pregnancy 8-9 weeks after transfer in pregnant participants (late OHSS)
Reported as:
Number · percentage of participants
Proportion of Subjects With OHSS, Overall and by Grade, and Proportion of Subjects With Moderate/Severe OHSS
percentage of participantsFE 999049 (Follitropin Delta)Placebo
OHSS (any grade)2.40
OHSS (moderate/severe)1.50
SecondaryProportion of Subjects Hospitalized Due to OHSS and Proportion of Subjects Undergoing Paracentesis Due to OHSS

Percentage of participants hospitalized or undergoing paracentesis due to OHSS are reported

Time frame:
≤9 days after triggering of final follicular maturation (early OHSS), >9 days after triggering of final follicular maturation until 21-28 days after last IMP dose or up to ongoing pregnancy 8-9 weeks after transfer in pregnant participants (late OHSS)
Reported as:
Number · percentage of participants
Proportion of Subjects Hospitalized Due to OHSS and Proportion of Subjects Undergoing Paracentesis Due to OHSS
percentage of participantsFE 999049 (Follitropin Delta)Placebo
Hospitalization00
Paracentesis00
SecondaryProportion of Participants With Multi-fetal Gestation in the Fresh Cycle

Defined as pregnancy with more than one fetus. Among participants with ongoing pregnancy, percentage of participants with twin pregnancies are presented. '%' in the unit of measure refers to 'percentage'.

Time frame:
Up to 8-9 weeks after transfer
Reported as:
Number · % of participants with twin pregnancy
Proportion of Participants With Multi-fetal Gestation in the Fresh Cycle
% of participants with twin pregnancyFE 999049 (Follitropin Delta)
Proportion of Participants With Multi-fetal Gestation in the Fresh Cycle2.6
SecondaryProportion of Cryopreserved Cycles With Multi-fetal Gestation

Defined as pregnancy with more than one fetus. Among cryopreserved cycles with ongoing pregnancy, percentage of cycles with twin pregnancies are presented. '%' in the unit of measure refers to 'percentage'.

Time frame:
Up to 8-9 weeks after transfer
Reported as:
Number · % of cycles with twin pregnancy
Proportion of Cryopreserved Cycles With Multi-fetal Gestation
% of cycles with twin pregnancyFE 999049 (Follitropin Delta)
Proportion of Cryopreserved Cycles With Multi-fetal Gestation3.4
SecondaryBiochemical Pregnancy, Spontaneous Abortion, Ectopic Pregnancy (With and Without Medical/Surgical Intervention) and Vanishing Twins in the Fresh Cycle

The percentage of participants with biochemical pregnancy, spontaneous abortion, ectopic pregnancy (with and without medical/surgical intervention) and vanishing twins in the fresh cycle are presented. Data represents participants with positive βhCG. Data is not shown for placebo arm because no participants had a positive βhCG. '%' in the unit of measure refers to 'percentage'. Unit: % of participants with early pregnancy loss.

Time frame:
Up to 8-9 weeks after transfer
Reported as:
Number · % of participants
Biochemical Pregnancy, Spontaneous Abortion, Ectopic Pregnancy (With and Without Medical/Surgical Intervention) and Vanishing Twins in the Fresh Cycle
% of participantsFE 999049 (Follitropin Delta)
Biochemical pregnancy15.8
Spontaneous abortion15.2
Induced abortion0.0
Ectopic pregnancy0.6
SecondaryBiochemical Pregnancy, Spontaneous Abortion, Ectopic Pregnancy (With and Without Medical/Surgical Intervention) and Vanishing Twins in the Cryopreserved Cycles

The percentage of cryopreserved cycles with biochemical pregnancy, spontaneous abortion, ectopic pregnancy (with and without medical/surgical intervention) and vanishing twins are presented. Data is not shown for placebo arm because no participants had a positive βhCG. '%' in the unit of measure refers to 'percentage'.

Time frame:
Up to 8-9 weeks after transfer
Reported as:
Number · % of cycles with early pregnancy loss
Biochemical Pregnancy, Spontaneous Abortion, Ectopic Pregnancy (With and Without Medical/Surgical Intervention) and Vanishing Twins in the Cryopreserved Cycles
% of cycles with early pregnancy lossFE 999049 (Follitropin Delta)
Biochemical pregnancy16.8
Spontaneous abortion18.9
Induced abortion0.0
Ectopic pregnancy1.1
SecondaryProportion of Participants With Technical Malfunctions of the Administration Pen

Incidences of technical malfunctions of the administration pen were recorded.

Time frame:
Up to 20 stimulation days
Reported as:
Number · percentage of participants
Proportion of Participants With Technical Malfunctions of the Administration Pen
percentage of participantsFE 999049 (Follitropin Delta)Placebo
Proportion of Participants With Technical Malfunctions of the Administration Pen00

Adverse events

Collected over The AEs were recorded from time of signing informed consent to end-of-trial (up to Ongoing pregnancy visit (10-11 weeks after transfer)). Data for the AEs is presented for the fresh cycle and cryopreserved cycle.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FE 999049 (Follitropin Delta)0/533 (0%)2/533 (0.4%)151/533 (28.3%)
Placebo0/54 (0%)0/54 (0%)2/54 (3.7%)
Most frequent serious events
Most frequent serious events
EventFE 999049 (Follitropin Delta)Placebo
Ectopic pregnancyPregnancy, puerperium and perinatal conditions1/5330/54
Hyperemesis gravidarumPregnancy, puerperium and perinatal conditions1/5330/54
Most frequent other events
Most frequent other events
EventFE 999049 (Follitropin Delta)Placebo
Procedural painInjury, poisoning and procedural complications111/5330/54
Abortion spontaneousPregnancy, puerperium and perinatal conditions32/2450/54
Biochemical pregnancy (Cryopreserved cycle)Pregnancy, puerperium and perinatal conditions29/2450/54
Morning sicknessPregnancy, puerperium and perinatal conditions27/2450/54
HeadacheNervous system disorders29/5332/54
Biochemical pregnancy (Fresh cycle)Pregnancy, puerperium and perinatal conditions27/5330/54

Baseline characteristics

The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment.

Age, Continuous
Age, Continuous(years)FE 999049 (Follitropin Delta)PlaceboTotal
Mean37.7 ± 2.137.9 ± 2.137.7 ± 2.1
Sex: Female, Male
Sex: Female, Male(Participants)FE 999049 (Follitropin Delta)PlaceboTotal
Female53354587
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FE 999049 (Follitropin Delta)PlaceboTotal
Hispanic or Latino57966
Not Hispanic or Latino47645521
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FE 999049 (Follitropin Delta)PlaceboTotal
American Indian or Alaska Native202
Asian57562
Native Hawaiian or Other Pacific Islander505
Black or African American70474
White39845443
More than one race000
Unknown or Not Reported101
Body mass index (BMI)
Body mass index (BMI)(kg/m^2)FE 999049 (Follitropin Delta)PlaceboTotal
Mean27.0 ± 5.127.9 ± 5.127.0 ± 5.1
Primary infertility
Primary infertility(participants)FE 999049 (Follitropin Delta)PlaceboTotal
Number22626252
Duration of infertility
Duration of infertility(months)FE 999049 (Follitropin Delta)PlaceboTotal
Mean42.7 ± 37.645.9 ± 43.243.0 ± 38.1
Primary reason for infertility
Primary reason for infertility(Participants)FE 999049 (Follitropin Delta)PlaceboTotal
Unexplained infertility25128279
Tubal infertility1207127
Mild male factor50555
Moderate male factor62870
Severe male factor27431
Endometriosis stage I/II20222
Endometriosis stage III/IV101
Other202
08

Study locations

24 sites
  • Fertility Treatment Center
    Tempe, Arizona 85284, United States
  • HRC Fertility
    Encino, California 91436, United States
  • Center for Advanced Reproductive Services PC
    Farmington, Connecticut 06032, United States
  • Reproductive Associates of Delaware
    Newark, Delaware 19713, United States
  • Women's Medical Research Group, LLC
    Clearwater, Florida 33759, United States
  • Center for Reproductive Medicine
    Winter Park, Florida 32789, United States
  • Fertility Institute of Hawaii, INC
    Honolulu, Hawaii 96814, United States
  • Fertility Centers of Illinois (RH)
    Chicago, Illinois 60610, United States
  • InVia Fertility
    Hoffman Estates, Illinois 60169, United States
  • Boston IVF
    Waltham, Massachusetts 02451, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Columbia University Fertility Center
    New York, New York 10019, United States
  • Reproductive Endocrinology Associates of Charlotte (REACH) S. Corporation
    Charlotte, North Carolina 28207, United States
  • Carolina Conceptions
    Raleigh, North Carolina 27607, United States
  • Institute for Reproductive Health
    Cincinnati, Ohio 45209, United States
  • Abington Reproductive Medicine
    Abington, Pennsylvania 19046, United States
  • Main Line Fertility Center
    Bryn Mawr, Pennsylvania 19010, United States
  • Fertility Associates of Memphis, PLLC
    Memphis, Tennessee 38120, United States
  • Center for Assisted Reproduction
    Bedford, Texas 76022, United States
  • Houston Fertility Institute
    Houston, Texas 77063, United States
  • Center of Reproductive Medicine
    Webster, Texas 77598, United States
  • Utah Fertility Center
    Pleasant Grove, Utah 84062, United States
  • Eastern Virginia Medical School | EVMS Obstetrics & Gynecology
    Norfolk, Virginia 23507, United States
  • Seattle Reproductive Medicine WA
    Seattle, Washington 98109, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Dec 2020, 25 months.

Results were first posted in Jan 2024, 3 years after primary completion. A results delay was requested in Nov 2021.

Of 28 phase 3 interventional studies under Infertility, Female, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's 25 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2018
First posted
Nov 13, 2018
StartActual
Oct 29, 2018
Primary completionActual
Dec 21, 2020
CompletionActual
Dec 21, 2020
Results delay requested
Nov 16, 2021
Results first posted
Jan 18, 2024
Last update
Jan 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03738618
Responsible party
Sponsor
First posted
Nov 13, 2018
Start date
Oct 29, 2018
Primary completion
Dec 21, 2020
Completion
Dec 21, 2020
Results posted
Jan 18, 2024
Last update
Jan 18, 2024

Study contacts

Global Clinical Compliance
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin delta

Start the discussion